- Meeting abstract
- Open Access
Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of neuropathy diabetes score (NDS) compared with the Michigan neuropathy screening instrument (MNSI)
© Nienov et al. 2015
- Published: 11 November 2015
- Metabolic Syndrome
- Gold Standard
- False Positive
MNSI is widely used for evaluation of distal symmetric peripheral polyneuropathy (PPN) in individuals with diabetes. In the DCCT/EDIC study, the MNSI was validated for screening of signs and symptoms of PPN, presenting, for a cutoff of ≥2.5, sensitivity of 61%, specificity of 79%, positive predictive value (PPV) of 55% and negative (NPV) of 83%, when compared to neurological examination in combination with nerve conduction studies as gold standard.
To evaluate the sensitivity, specificity, PPV, NPV and accuracy of Neuropathy Diabetes Score (NDS) (≥3.0) compared to MNSI score, used as the gold standard.
305 patients with Metabolic Syndrome, Diabetes (type 1 and type 2) were evaluated with MNSI and DNS.
When compared to MNSI as the gold standard, the NDS is a good instrument for evaluating presence of PPN, with high specificity, which reduces false positives, and good accuracy, which reflects the test precision.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.